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Background: Vertical bone augmentation (VBA) remains unpredictable and challenging for most clini-
cians. This study aims to compare hard tissue outcomes of VBA, with and without recombinant human
bone morphogenetic protein (rhBMP)-2, under space-making titanium mesh in a canine model.
Methods: Eleven male beagle dogs were used in the study. Experimental ridge defects were created to
form atrophic ridges. VBA was performed via guided bone regeneration using titanium mesh and allo-
grafts. In experimental hemimandibles, rhBMP-2/absorbable collagen sponge was well mixed with allo-
grafts prior to procedures, whereas a control buffer was applied within controls. Dogs were euthanized
after a 4-month healing period. Clinical and radiographic examinations were performed to assess ridge
dimensional changes. In addition, specimens were used for microcomputed tomography (micro-CT) as-
sessment and histologic analysis.
Results: Membrane exposure was found on five of 11 (45.5%) rhBMP-2–treated sites, whereas it was
found on nine of 11 (81.8%) non–rhBMP-2–treated sites. Within 4 months of healing, rhBMP-2–treated
sites showed better radiographic bone density, greater defect fill, and significantly more bone gain in
ridge height (P <0.05) than controls. Experimental hemimandibles exhibited lower rates of membrane ex-
posure and a noteworthy, ectopic bone formation above the mesh in 72% of sites. Results from micro-CT
also suggested a trend of less vertical bone gain and bone mineral density in controls (P >0.05). Under
light microscope, predominant lamellar patterns were found in the specimen obtained from rhBMP-2
sites.
Conclusion: With inherent limitations of the canine model and the concern of such a demanding sur-
gical technique, current findings suggest that the presence of rhBMP-2 in a composite graft allows an
increase of vertical gain, with formation of ectopic bone over the titanium mesh in comparison with
non–rhBMP-2 sites. J Periodontol 2017;88:896-905.
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R
idge deformities, horizontal and/or vertical, lead
to both functional and esthetic challenges of
dental implant treatments.1 A residual ridge
generally undergoes significant dimensional changes
after tooth extraction.2 Therefore, ridge corrective
procedures are often recommended to achieve opti-
mal treatment outcomes. Vertical bone augmentation
(VBA) has been regarded as one of the greatest
challenges due to anatomic limitations and technical
difficulties. Numerous surgical modalities that use
various materials have been introduced for VBA.3
These modalities include, but are not limited to,
distraction osteogenesis,4 monocortical onlay bone
grafting5, and guided bone regeneration (GBR).6
Based on the concept of compartmentalized wound
healing, GBR has been widely used for ridge aug-
mentation via the aids of barrier membranes.7-9 Pre-
vious researchers advocated predictable and promising
outcomes in regaining ridge width.6,9 In contrast, the
amount of vertical bone gain varied from2 to 8mmwith
a large range of complication (0% to 45.5%).3 Given
undesired wound healing, themajority of complications
lead to barrier membrane exposure, which results in
loss of graft materials and other unfavorable outcomes,
such as infection of bone graft, as well as membrane
contamination.10,11 For a predictable bone augmen-
tation, principles for GBR were proposed12 as key
requirements for bone regeneration. These principles,
forming the acronym PASS, include the following:
1) primary wound coverage to provide an undisturbed
environment for tissue/bone tomature; 2) angiogenesis
or blood supply to support needed undifferentiated
mesenchymal cells and growth factors in order for the
wound to heal; 3) space for tissue/bone to grow; and
4) stability to allow stable wound healing and tissue
maturation.12
Bone morphogenetic proteins (BMPs) belong to the
transforming growth factor b superfamily and possess
multiple functions.13 In addition to neural induction,
BMPs act as important signals for bone and cartilage
formation, especially in the cell differentiation andmatrix
synthesis stages.13,14 At the cellular level, binding of
BMPs to cell membranes brings a cascade of signal
transduction to the nucleus, enhancing activation of
specific target genes, which are responsible for wound
healing and tissue remodeling.15 In recent years, several
BMPs have been investigated for their osteoinductive
potential.16-22 In animal models or clinical trials, BMPs
were applied in combinationwith various carrier systems
for the purpose of bone regeneration in the procedures of
socket grafting,16,19 sinus grafting,20,21 periodontal
repair,22 localized bone augmentation,17,23 and implant
osseointegration.16,24 Previous literature has shown
that recombinant human bone morphogenetic protein
(rhBMP)-2 could not only promote osseointegration,
but also induce new bone formation in VBA.25,26
Despite the potential benefits of rhBMP-2 on VBA,
one main drawback of previous techniques is the use
of absorbablemembrane as a barriermembrane, since
this type of membrane is not rigid enough to hold the
space needed for the bone formation because of its
inability to prevent overlying soft tissue pressure, es-
pecially during VBA.12 Titanium meshes (Ti-meshes),
therefore, have been applied for GBR because of their
outstanding mechanical characteristics, which protect
bone materials, prevent mucosal compression, and
allow creation of space.27 Furthermore, there is only
limited evidence available that evaluates the effec-
tiveness of rhBMP-2 under Ti-meshes at both clinical
and histologic levels. Hence, the purpose of this study
is to compare hard tissue outcomes of VBA, with or
without rhBMP-2, under space-making Ti-mesh in a
canine model.
MATERIALS AND METHODS
Eleven 1-year-old male beagle dogs were used in this
study. All procedures involving the dogs were pre-
approved by the Animal Welfare Committee at King
Saud University, Riyadh, Saudi Arabia, and performed
at the King Saud University Eng. A.B. Research Center
For Growth Factors and Bone Regeneration, Riyadh,
Saudi Arabia. In these dogs, vertical defects were
created surgically in bimandibular premolar areas after
extraction of all premolars. After 4 months of wound
healing, vertical GBR was performed using a Ti-mesh¶
and human allografts# in combination with or without
rhBMP-2.**
Preparation of Experimental Defects
All surgical procedures were performed under general
anesthesia and localized anesthesia with 2% xylocaine
with 1:200,000 epinephrine. At the beginning of the
study (day 0), chronic experimental defects were sur-
gically created bilaterally in the mandibles after ex-
traction of all mandibular premolars via a full-thickness
flap approach. These subcrestal defects were 30 ·
8 mm (width · height). Primary closure was carefully
achieved to ensure smooth wound healing. The re-
maining canine dentition was thoroughly cleaned by
ultrasonic and hand instrumentation. All of the dogs
received regular oral hygiene maintenance and follow-
up at 2, 4, 8, and 16 weeks postoperatively until the
VBA surgery.
After soft tissue healing, study casts were obtained
from residual ridges on bilateral jaws under general
anesthesia. A customized measuring stent was later
fabricated on each study model using light-cured
acrylic resin†† as the reference of ridge alteration.
Fitted onto occlusal surfaces of adjacent teeth, this
¶ Osteo-Mesh, Osteogenics Biomedical, Lubbock, TX.
# enCore, Osteogenics Biomedical.
** Infuse, Medtronic, Memphis, TN.
†† Triad TruTray, Dentsply, York, PA.
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template was grooved in the mesial (10 mm away
from canine), center (midpoint of the edentulous
ridge), and distal aspects (10mmaway frommolar) of
the residual ridge.
Surgical Procedures
At day 120 (baseline), VBA was performed using Ti-
meshes and allografts, with (Fig. 1) or without rhBMP-2
(Fig. 2), by calibrated experienced surgeons (HW and
PM). A midcrestal incision was made at the chronic
experimental defects. Bilateral vertical releasing in-
cisions were performed at the line angles, extending
beyond the mucogingival junction. After reflection of
full-thickness flaps, the entire ridge defect was exposed
and carefully curetted to remove all granulation tissues
and soft tissue tags. To promote regional acceleratory
phenomenon28 and angiogenesis, cortical bone was
perforated by a small round bur (#1/2) until bleeding
was noticed. Subsequently, experimental defects were
augmented vertically using either the mixture of allo-
grafts and rhBMP-2/absorbable collagen sponge (ACS)
on the experimental sides (left side), or the combination
of allografts and buffer/ACS on the control sides (right
sides). Prior to the procedure, an ACS was minced and
soaked into either rhBMP-2 (1.5 mg/mL) or a control
buffer for 15 minutes. Carrying rhBMP-2 or control
buffer, the minced ACS was well incorporated with
allografts and placed on the exposed atrophic ridge
until it was level to the adjacent bone. A Ti-mesh was
later applied to cover the entire augmented area and
stabilized with titanium fixation screws.‡‡ Periosteal
releasing incisions were made before suturing to ensure
flap approximation and tension-free primary wound
closure. Amoxicillin (25 mg/kg) was administered via
intramuscular injection once a day for 5 days to pre-
vent possible infection. Sutures were removed 2 weeks
after surgery. Regular plaque control was continued
postoperatively, as mentioned previously.
Three dogs were euthanized at day 240, i.e., 4
months after VBA procedures (P4M), using an over-
dose of 3% sodium pentobarbital, for histologic anal-
ysis and microcomputed tomography (micro-CT)
scans. Jaw blocks were obtained from canines to first
molar bilaterally.
Clinical and Radiographic Assessments
Occurrence of adverse events during healing pe-
riods were recorded. Clinical and radiographic
parameters were assessed to investigate changes of
ridge dimension and bone density. Clinically, ridge
height alteration (RHA) was defined as vertical
distances between the crestal level of soft tissue and
the above-mentioned measuring template, taken at
baseline (immediately before surgery, RHA1) and
P4M (RHA2). Overall vertical bone gain in clinical
measurements (VBGc) was calculated as the dif-
ference between RHA1 and RHA2. Using the cus-
tomized measuring template, RHA was measured
using a UNC probe§§ by a single examiner (YH). To
assess changes in bone density, standardized per-
iapical radiographs with the aids of bite registration
Figure 1.
GBR procedure using allograft and Ti-meshes in combination with rhBMP-2 in the experimental side. A) Chronic ridge defect at 4 months after tooth
extractions and ridge creation. B) Preoperative measurement. C) Decortication. D) GBR procedure using allograft and Ti-meshes in combination with
rhBMP-2. E) Suture. F) Postoperative view after a healing period of 4 months.
‡‡ Pro-fix, Osteogenics Biomedical.
§§ UNC probe, Hu-Friedy, Chicago, IL.
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materials were taken immediately before and im-
mediately after GBR and at P4M.
Histologic Analysis and Micro-CT Scans
As part of the project, only three dogs were euthanized
at this point. Therefore, bone mineral density (BMD)
and VBG in micro-CT analysis (VBGct) were assessed
on these dogs. Jaw blocks obtained from the three
dogs were scanned entirely using micro-CT scan as-
sessments prior to specimen preparation. The samples
were three-dimensionally evaluated using a micro-CT
systemii with a voltage of 101 kV and current of 96 mA.
Resolution was 37.41-mm pixels. Reconstruction and
measurements of these data images were performed
with evaluation software provided by the manufac-
turer. Parameters included the following: 1) BMD and
2) VBGct, measuring the increase of vertical ridge
height in mesial, center, and distal aspects.
Jaw blocks and tissue samples were immediately
fixed in 10% buffered formalin at room temperature.
Because hard tissue formation was observed above
and beneath the Ti-meshes on several sites, trephines
were used to obtain tissue samples from the regen-
erated bone, to preserve the layer structure during
specimen fixation. The trephines were carefully re-
moved prior to subsequent processes. All samples
were decalcified for 20 days and embedded in paraffin.
Being divided in an axial plane, 4-mm sections were
subsequently deparaffinized, rehydrated, and stained
with hematoxylin and eosin (H&E) staining.
Bone histomorphometric analysis was performed
semiautomatically on cross sections of augmented
hemimandibles using H&E staining. Ten randomly
selected images were assessed using a fluorescence
microscope equipped with a ·10 objective lens and
a digital microscope camera¶¶ connected to a com-
puter. The images were evaluated by a single examiner
(FO) with imaging software## to quantify vital bone,
which was presented as area and percentages of each
component. Using the alveolar crestal levels of first
molars as references, percentages of regenerated bone
height were also calculated from these specimens.
Statistical Analyses
Datawere analyzed using a statistical analysis software
package.*** Results with P <0.05 were considered
statistically significant. Based upon the power cal-
culation, to reach a power of 0.8, 11 dogs (sample
size = 10.17) were required, assuming that the mean
difference and standard deviation in bone height gain
between the two groups were 2.0 and 1.0 mm, re-
spectively, with P = 0.05. As a pilot study with limited
sample sizes, Wilcoxon signed-rank sum test was used
to examine differences of parameters between control
and experimental sides and the differences between
Figure 2.
GBR procedure using allograft and Ti-meshes in the control side. A) Chronic ridge defect at 4 months after tooth extractions and ridge creation.
B) Preoperative measurement. C) Decortication. D) GBR procedure using allograft and Ti-meshes. E) Suture. F) Postoperative view after a healing
period of 4 months.
ii SkyScan 1172, CT-Analyser version 1.11.4.2+, SkyScan, Kontich,
Belgium.
¶¶ DP70, Olympus, Barcelona, Spain.
## ImageJ, National Institutes of Health, Bethesda, MD.
*** JMP 6.0. Statistical Discovery, SAS Institute, Cary, NC.
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baseline and P4M. In addition, the Wilcoxon rank sum
test was applied to compare differences in results
between sites with or without membrane exposure.
RESULTS
After a 4-month healing period, nine of 11 control sides
(81.8%) experienced membrane exposure, whereas
only five of 11 experimental sides (45.5%) had
membrane exposure. In those sites with membrane
exposure, moderate inflammation and infection were
noticed with the signs of redness, oozing, and notable
swelling. All device exposures were noticed 6 to 8
weeks after VBA procedures. Membranes were there-
fore removed once the exposure was noticed. Clinical
outcomes are shown in Table 1. No significant differ-
ences were found among groups at baseline. From
baseline to P4M, RHA barely changed in the control
sides in all aspects (P >0.05). In contrast, RHA in-
creased significantly in the experimental sides. In
comparisons of experimental and control groups, dif-
ferences in VBGc reached statistical significance
(P <0.05) at the center and distal aspects of the surgical
areas. Bone fill was 29.0% (mesial), 48.4% (center),
and 52.7% (distal) in the experimental hemimandible,
whereas the control groups only had bone fills of 20.4%
(mesial), 8.5% (center), and -3.1% (distal).
Table 2 shows results of VBGc measured from sites
with or withoutmembrane exposure. In rhBMP-2 groups
sites with no membrane exposure had significantly
greater (P <0.05) VBGc than those with membrane
exposure in mesial and center aspects of surgical fields.
Although similar trends were found in controls, differ-
ences did not reach statistical significance (P >0.05).
At P4M it was also noteworthy that hard tissue was
found above themembrane (Fig. 3) in eight of the 11
experimental hemimandibles. However, none of the
control sides exhibited the same phenomenon.
Obtained by trephine to preserve layer structure, the
components of these hard tissues were further in-
vestigated by histologic assessment.
Changes of bone density were evaluated using
standardized periapical radiographs taken immedi-
ately before GBR and at P4M. Bone density was equal
in both control and test hemimandibles at baseline. At
P4M, bone density on augmented regions increased
predominantly in the rhBMP-2–treated hemimandibles,
and lower bone density was shown on the controls.
BMDand VBGct (Table 3) were assessed on the three
dogs using micro-CT scan analysis. Slightly greater
BMD was also found in the rhBMP-2 groups than con-
trols (1.28 – 0.30 g/mm3 versus 1.13 – 0.24 g/mm3).
Nonetheless, differences among groups were not sta-
tistically significant (P >0.05). In the control group,
VBGct was 4.64 – 0.46 mm (58.0%), 3.49 – 0.66 mm
(43.6%), and 3.59 – 0.37 mm (44.9%) at the mesial,
center, and distal aspects of the edentulous ridge, re-
spectively. On the other hand, rhBMP-2 hemimandibles
gained 6.23 – 2.40 mm (77.9%), 5.15 – 1.40 mm
(64.4%), and 4.89 – 2.48 mm (61.3%) in all three as-
pects. Although differences between the groups did not
reach statistical significance (P >0.05), results showed
a trend of greater VBGct in rhBMP-2–treated sites.
Histologic analysis revealed close contacts between
new bone and original cortical bone surfaces with no
evidence of fibrous tissue intervention. Specimens
obtained from experimental sites showed uneventful
healing with some signs of chronic inflammation under
the light microscope (Fig. 3A). In addition, bone tissue
formation was observed above and beneath Ti-meshes
(Fig. 3B). Under light microscope observation, hard
tissues obtained above Ti-meshes in rhBMP-2 sites
were confirmed as newly regenerated bone with a cor-
tical (Figs. 3C and 3D) and trabecular pattern. These
specimens showed a predominately lamellar pattern,
revealing a Haversian system with concentric lamel-
lae, central canals, and lacunae. In the experimental
Table 1.
Clinical Outcomes: RHA and VBGc (mean 6 SD)
Group Parameters
Location
Control (n = 11) Test (n = 11)
RHA1 (mm) RHA2 (mm) VBG (mm) Bone fill (%) RHA1 (mm) RHA2 (mm) VBG (mm) Bone fill (%)
Mesial (10 mm away
from canine)
4.61 – 2.23 3.73 – 1.42 0.94 – 2.40 20.39 5.0 – 1.79 3.55 – 1.69 1.45 – 2.84 29.0
Center (midpoint of
the edentulous
ridge)
5.86 – 1.98 5.82 – 1.78 0.05 – 2.20* 8.53 7.23 – 1.54† 3.73 – 3.69† 3.50 – 2.73* 48.41
Distal (10 mm away
from molar)
5.73 – 1.49 5.91 – 1.51 -0.18 – 1.33* -3.14 6.55 – 2.58† 3.09 – 2.17† 3.45 – 2.67* 52.67
* Statistically significant (P <0.05) difference in VBG between controls and test sites.
† Statistically significant (P <0.05) difference between RHA1 and RHA2.
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hemimandible, an increase of trabecular bone was
also observed morphometrically. Differences among
groups reached statistical significance (P <0.05) in
favor of rhBMP-2–treated sites (4.06 – 2.25 mm2) in
comparison with control sites (2.96 – 1.62 mm2).
DISCUSSION
This study examines effects of rhBMP-2 incorporated
with human allografts and Ti-meshes for VBA. In the
present findings, rhBMP-2 incorporated with human
allografts and Ti-meshes appears to achieve greater
augmented bone vertically (average of 5.42 versus
3.90mm), greater bone fill and VBGc, and lower risks of
membrane exposure than sites treated without rhBMP-
2. Considering the possible impacts of membrane ex-
posure, results could have been more promising on
both sites. No immunologic or adverse reactions were
noticed in the histologic level from the present results.
Under light microscopic observation, samples from
rhBMP-2 groups exhibitedmoremineral components of
newly formed tissues. It appeared in the present results
that rhBMP-2 possesses regenerative potential in spite
of potential adverse effects of rhBMP-2.
In the present study, ridge defects were created and
re-entered after a healing period of 4 months. These
chronic ridge defects were made purposely to reduce
potential for regeneration, which is commonly observed
in a freshly created defect. Results showed that rhBMP-2
may benefit vertical bone gain with the application of
GBR. Mean bone fills were 29.0%, 48.4%, and 52.7%
in mesial, center, and distal aspects of experimental
hemimandibles, respectively. Meanwhile, controls ex-
hibitedminimal gain or even loss of vertical bone during
the study period. These results corresponded well with
previous findings from other animal models.15,17,25 In
a series of studies, Wikesjo¨ and coworkers15,25 exam-
ined the regenerative potential of rhBMP-2 along with
a calcium-phosphate cement carrier, using a model
with a 5 mm suprabony defect created surgically
around implants. Promising results were observed in
rhBMP-2–treated groups, including radiographic
bone regeneration and clinically uneventful healing.
In histometric analysis, 89% to 95% of defect height
was made up of regenerated bone in rhBMP-2–treated
sites compared with 7% in controls.15 Subsequently,
the potential of rhBMP-2 in VBA was further in-
vestigated in GBR using expanded polytetrafluoro-
ethylene (ePTFE) membrane for space creation.
Compared with controls, an additional 2.9- to 3.5-mm
vertical bone gain was obtained in sites treated with
rhBMP-2/ACS.25 Investigating results from GBR pro-
cedures, the same group reported higher bone fill in
sites receiving rhBMP-2/ACS or rhBMP-2/GBR than
controls.17 Indeed, a more recent study proved ad-
ditional benefits of the bone substitute materials used
in conjunction with rhBMP-2/ACS in an animal GBR
model.26 From these studies, it can be suggested that
addition of bone graft materials to the rhBMP-2 en-
hances predictability of VBA.
From a tissue-engineering standpoint, use of Ti-
mesh not only provides space needed for rhBMP-2/
ACS to induce bone formation but also directs the
geometry of newly formed bone.29 Adopting these
principles, de Freitas and coworkers30 achieved prom-
ising horizontal ridge augmentation from rhBMP-2/
ACS application in combination with Ti-meshes, which
provided space creation and wound stability. In the
present study, it is noteworthy that 72.7% of exper-
imental sites exhibited ectopic bone formation to
a certain degree, which was rarely reported previously.
This phenomenon could be ascribed to the rapid and
strong interaction between proteins and scaffolds.31,32
Bone regeneration using direct gene delivery of BMPs
has been investigated in ectopic animal models, sug-
gesting the osteogenesis properties of these proteins.31
Depending on the size of the pores and interconnectivity
of protein and grafting materials, previous researchers
claimed penetration of bone tissue results from rapid
protein resorption to the porous alloplastic mate-
rials used in their models and is therefore limited to
Table 2.
Clinical Outcomes: VBGc (mean 6 SD) in Sites With and Without Membrane Exposure
Group
Control Test
Membrane
exposure (mm)
Membrane
non-exposure (mm) P value
Membrane
exposure (mm)
Membrane
non-exposure (mm) P value
Number of sites 9 2 5 6
VBGc mesial 0.36 – 2.36 3.00 – 1.41 0.23 -0.80 – 1.10 3.80 – 2.38 0.01*
VBGc center -0.28 – 2.31 1.50 – 0.71 0.19 1.00 – 1.22 5.58 – 1.50 0.01*
VBGc distal -0.22 – 1.39 0 – 1.41 0.90 2.4 – 1.14 4.33 – 3.39 0.10
* Statistically significant (P <0.05).
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the periphery of scaffolds.32 From the anatomic shape
of the new vital bone over the Ti-mesh in the current
study, the authors suggest the ectopic bone forma-
tion may be related to mesenchymal cells from the
periosteum instead of from underlying bone.
Success of GBR relies on primary closure of the soft
tissues. In fact, membrane exposure has been con-
sidered a critical drawback of GBR.3 Although Lindfors
et al.33 suggested that membrane exposure may not
show a negative impact on GBR outcomes using
a titanium-reinforced ePTFE membrane, both meta-
analysis and clinical studies suggested that exposure
of barrier devices often impair GBR outcomes,34,35
resulting from inflammatory tissue reactions and
bacterial contamination.36,37 A previous human study
using titanium-reinforced barriers on VBA showed
Figure 3.
Hard tissue outcomes in the experimental side. A) Photomicrograph of mandible bone tissue in area of experimental defect. Note the severe
inflammatory infiltrate on the surface. (H&E; original magnification ·4.) B) Photograph of mandible section of dog on the experimental side. New
bone formation above Ti-mesh in a test animal treated with allograft plus rhBMP-2 can be observed. C) Photomicrograph of vascularized cancellous
bone formed above titanium mesh with an area of mesenchymal tissue showing the remaining bone allograft tissue. (H&E; original magnification ·4.)
D) Photomicrograph of mandible bone tissue in experimental defect area. Note connective tissue and absence of inflammatory infiltrate over new
cancellous bone tissue in an animal treated with allograft plus rhBMP-2 (test group). (H&E; original magnification ·4.)
Table 3.
Micro-CT Assessment: VBGct and BMD
Dog Number Location
VBGct (mm)
Mesial (mm) Center (mm) Distal (mm) BMD (g/mm3)
1 Control (right) 4.11 3.11 3.16 0.85
Test (left) 4.39 5.05 4.84 0.94
2 Control (right) 4.84 4.25 3.80 1.23
Test (left) 5.36 3.80 2.44 1.39
3 Control (right) 4.98 3.11 3.80 1.30
Test (left) 8.95 6.60 7.40 1.52
Mean – SD (%) Control (right) 4.64 – 0.46 (58.0) 3.49 – 0.66 (43.63) 3.59 – 0.37 (44.88) 1.13 – 0.24
Test (left) 6.23 – 2.40 (77.9) 5.15 – 1.40 (64.4) 4.89 – 2.48 (61.3) 1.28 – 0.30
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a complication rate of 40%.38 In addition, 42% of
membrane exposure rate (three of seven of the sites)
was reported in an earlier canine study using rhBMP-2
for bone reconstruction.17 These results corresponded
to the current findings. Since most of the complica-
tions occurred in the first group of dogs, the authors
believe the occurrence of membrane exposure could
be ascribed to the learning curve during surgical
procedures. The high membrane exposure rate in the
current study could be ascribed to the learning curve
of the research team in terms of preparation protocol,
surgical procedures, and postoperative care protocol.
In addition to postoperative tissue retraction due to
flap edema and inflammatory responses, animal be-
havior regarding their exertion of detrimental biting
mechanism for pain relief could be another expla-
nation. It is presumed that any effect of these ani-
mal-mediated conditions could occur in one animal
with the same intensity in the experimental as in the
control site. Despite the surgeries being conducted
by the same surgeons, with the same materials
(except the application of rhBMP-2), and the split-
mouth design, a lower percentage of membrane
exposure (45.5%) was found on the test sites than
the controls (81.8%) in the present study. In pre-
vious literature, endogenous BMPs have been con-
firmed to activate the BMP pathway in blood vessels
and enhance tissue repair through angiogenesis by
inducing vascular endothelial growth factor-A or
through pericyte activation.39 Given reports in the
literature and the present results, it appears that
experimental sites healed more quickly than control
sites. One could speculate that exogenous BMP may
have a role in accelerating angiogenesis in the
wound in the very early stages, rather than this being
a miraculous effect of the protein.
Usage of BMPs shows some controversial aspects as
differentiation factors or as chemotactic agents.14
They stimulate angiogenesis, migration, proliferation,
and differentiation of stem cells from the surrounding
mesenchymal tissues in an area of injury.14 As a ge-
netically engineered human protein, rhBMP-2 is se-
creted from Chinese hamster ovary cells encoding the
human rhBMP-2 protein gene and is approved for
spinal fusion and tibia repair by the US Food and Drug
Administration (FDA). Certain oral and maxillofacial
uses, such as sinus augmentation and localized alve-
olar ridge augmentation used for the defect associated
with the extraction socket, were also approved by
the FDA.40 However, the controversy surrounding
agents has been raised recently in regard to multiple
complications associated with spinal surgeries. As
a reflection, the Yale University Open Data Access
(YODA) Project was conducted to review these con-
cerns.41 In 2013, two reports42,43 were published with
several important findings: 1) there was no significant
difference in fusion rates between rhBMP-2 and iliac
crest autograft; 2) similar rates of retrograde ejacula-
tion and neurologic complications were found to be
associated with the uses of rhBMP-2 and autograft iliac
crest bone graft in the procedures of anterior cervical
fusion or posteriolateral fusion; 3) high complication
rates were found in anterior cervical fusion and pos-
terior lumbar procedures in terms of ectopic bone
formation; and 4) the absolute risk of cancer with use
of BMP-2 remained minimal.42 Similar concerns of
carcinogenesis have been raised with regard to use of
BMP-2 in oral and maxillofacial procedures.44,45 In
vitro and animal studies showed an adverse effect on
cell invasion and potential effects on oral squamous
cell carcinoma, thereby raising concerns for the safety
of rhBMP-2 applications for bone reconstruction in
patients with oral cancer.43,44 In spite of these con-
cerns, the authors recommend considering the com-
bination of BMP-2 andGBR as a possible alternative for
bone reconstruction in selected healthy patients when
the iliac crest autograft is not available because of the
following reasons: 1) similar regenerative potential of
bone formation can be achieved in both approaches:
combination of BMP-2 and GBR had fewer ex-
penses and less morbidity compared with iliac auto-
grafts;42,43,46 2) the absolute risk of cancer with the
use of BMP-2 remained minimal as results of YODA
projects show; 3) to date, no clinical report in the
dental field has shown the presence of life-threatening
complications, such as swallowing/breathing diffi-
culties, after use of BMP-2 in sinus lifts, socket aug-
mentation, or ridge augmentation. Nevertheless, it is
the responsibility of the clinician to inform the patient
about these risks prior to treatment.
Limitations of this study include the small sample
sizes, short experimental periods, and the lower evi-
dence level associated with an animal model com-
pared with clinical trials. To facilitate the investigation
of healing outcomes, qualifying measurements of
initial soft tissue healing and quantities of soft tissue
flap should be included to evaluate contributing factors
of membrane exposure. Clinical trials with longer
follow-up time are still needed to provide the impacts
of rhBMP-2 on VBA in a long-term setting.
CONCLUSIONS
With inherent limitations of the canine model and the
concern of such a demanding surgical technique,
current findings suggest that presence of rhBMP-2 in
combinationwith allograft allows an increase of vertical
gain with formation of ectopic bone over the Ti-mesh
comparedwith non–rhBMP-2 sites. Based on histologic
analysis, rhBMP-2 may induce vital bone formation
within a healing period of 4months. Further studies are
necessary with a larger population to evaluate the long-
term effects of rhBMP-2 on bone regeneration in humans,
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as well as the potential adverse effects of rhBMP-2 on
clinical oral and maxillofacial uses.
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